

	Overall	Training cohort	Testing cohort
5-year survival, N (%)	1786 (35.64)	941 (36.11)	845 (35.14)

	Overall	Training cohort	Testing cohort
Demographic information			
Age, mean (SD), yrs	62.52 (11.35)	61.24 (10.96)	63.90 (11.60)
Gender, N (%)			
Female	2512 (50.13)	1323 (50.77)	1189 (49.44)
Male	2499 (49.87)	1283 (49.23)	1216 (50.56)
BMI, median [IQR], kg/m2	23.42 [21.48 – 25.77]	25.53 [21.49 – 25.88]	23.34 [21.41 – 25.63]
Smoking, N (%)			
No	2832 (56.52)	1435 (55.07)	1397 (58.09)
Quit	1181 (23.57)	680 (26.09)	501 (20.83)
Yes	998 (19.92)	491 (18.84)	507 (21.08)
Drinking, N (%)			
No	4098 (81.78)	2204 (84.57)	1894 (78.75)
Quit	95 (1.90)	63 (2.42)	32 (1.33)
Yes	818 (16.32)	339 (13.01)	479 (19.92)
Betel chewing, N (%)			
No	4820 (96.19)	2507 (96.20)	2313 (96.17)
Quit	102 (2.04)	66 (2.53)	36 (1.50)
Yes	89 (1.78)	33 (1.27)	56 (2.33)

	Overall	Training cohort	Testing cohort
Cancer condition			
Cancer type, N (%)			
Adenocarcinoma	4135 (82.52)	2170 (83.27)	1965 (81.70)
Squamous Cell Carcinoma	798 (15.92)	391 (15.00)	407 (16.92)
Large Cell Carcinoma	78 (1.56)	45 (1.73)	33 (1.37)
Cancer stage, N (%)			
Stage = 1	637 (12.71)	240 (9.21)	397 (16.51)
Stage = 2	174 (3.47)	72 (2.76)	102 (4.24)
Stage = 3	879 (17.54)	426 (16.35)	453 (18.84)
Stage = 4	3321 (66.27)	1868 (71.68)	1453 (60.42)
Surgery, N (%)			
No	3469 (69.23)	1853 (71.11)	1616 (67.19)
Yes	1542 (30.77)	753 (28.89)	789 (32.81)
Radiation therapy, N (%)			
No	3024 (60.35)	1514 (58.10)	1510 (62.79)
Yes	2055 (41.01)	1092 (41.90)	895 (37.21)
Chemotherapy therapy, N (%)			
No	1728 (34.48)	848 (32.54)	880 (36.59)
Yes	3283 (65.52)	1758 (67.46)	1525 (63.41)
Targeted therapy, N (%)			
No	1956 (58.99)	1587 (60.90)	1369 (56.92)
Yes	2055 (41.01)	1019 (39.10)	1036 (43.08)
Immunotherapy, N (%)			
No	4849 (96.77)	2472 (94.86)	2377 (98.84)
Yes	162 (3.23)	134 (5.14)	28 (1.16)

	Overall	Training cohort	Testing cohort
Comorbidity, N (%)			
Hypertension	857 (17.10)	369 (14.16)	488 (20.29)
Hyperlipidemia	113 (2.26)	48 (1.84)	65 (2.70)
Myocardial infarction	8 (0.16)	5 (0.19)	3 (0.12)
CHF	41 (0.82)	8 (0.31)	33 (1.37)
CVA or TIA	81 (1.62)	43 (1.65)	38 (1.58)
Dementia	5 (0.10)	2 (0.08)	3 (0.12)
Chronic pulmonary disease	663 (13.23)	344 (13.20)	319 (13.26)
Connective tissue disease	24 (0.48)	11 (0.42)	13 (0.54)
Peptic ulcer disease	101 (2.02)	56 (2.15)	45 (1.87)
Mild liver disease	71 (1.42)	22 (0.84)	49 (2.04)
Uncomplicated diabetes	185 (3.69)	93 (3.57)	92 (3.83)
End-organ damage diabetes	8 (0.16)	0 (0)	8 (0.33)
Hemiplegia	7 (0.14)	6 (0.23)	1 (0.04)
Renal disease	38 (0.76)	13 (0.50)	25 (1.04)
Localized Solid tumor	4999 (99.76)	2604 (99.92)	2395 (99.58)
Metastatic Solid tumor	1529 (30.51)	764 (29.32)	765 (31.81)
Lymphoma	3 (0.06)	0 (0)	3 (0.12)
Depression	31 (0.62)	19 (0.73)	12 (0.50)
Anemia	36 (0.72)	10 (0.38)	26 (1.08)
Parkinson's disease	19 (0.38)	7 (0.27)	12 (0.50)
CCI score, median [IQR]	5.00 [3.00 – 9.00]	5.00 [3.00 – 9.00]	5.00 [4.00 – 9.00]

	Overall	Training cohort	Testing cohort
Laboratory test			
HB, mean (SD)	11.71 (1.95)	11.92 (1.93)	11.49 (1.96)
WBC, median [IQR]	6.80 [5.20 – 8.90]	6.70 [5.10 – 8.70]	6.95 [5.31 – 9.10]
BUN, median [IQR]	16.00 [12.00 – 21.00]	15.00 [12.00 – 19.00]	17.00 [13.00 – 22.30]
CREA, median [IQR]	0.84 [0.68 – 1.07]	0.84 [0.68 – 1.05]	0.82 [0.70 – 1.10]